MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 894 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
p38α inhibitor 8
CAS:p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.Fórmula:C17H13FN6Cor e Forma:SolidPeso molecular:320.324J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Fórmula:C38H32N2O12Pureza:98%Cor e Forma:SolidPeso molecular:708.67EBI-1051
CAS:EBI-1051 is a highly potent and orally efficacious inhibitor of MEK (IC50: 3.9 nM).Fórmula:C18H15F2IN2O5Pureza:98%Cor e Forma:SolidPeso molecular:504.22HPK1 ligand-Linker Conjugate 1
CAS:HPK1 ligand-Linker Conjugate 1 is a synthetic target protein ligand-linker compound used in the synthesis of PROTACs, such as PROTACHPK1 Degrader-5. PROTACHPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity.Fórmula:C19H21N3O7SCor e Forma:SolidPeso molecular:435.45HPK1-IN-42
CAS:HPK1-IN-42 (compound 185) is an inhibitor of HPK1, displaying potent activity with an IC50 of 0.24 nM [1].Fórmula:C26H30N6OSCor e Forma:SolidPeso molecular:474.62SOS1-IN-9
SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).Fórmula:C22H28F3N5OCor e Forma:SolidPeso molecular:435.49KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Fórmula:C32H37N7O3Pureza:98%Cor e Forma:SolidPeso molecular:567.68KRAS inhibitor-37
CAS:KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10p38 Kinase inhibitor 8
CAS:<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Fórmula:C22H21FN6O2Cor e Forma:SolidPeso molecular:420.44VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Fórmula:C25H30ClFN2O6S2Cor e Forma:SolidPeso molecular:573.097Lambertellin
CAS:<p>Lambertellin, an effective antibiotic, acts as both a bactericide and fungicide. It exerts anti-inflammatory effects in LPS-stimulated RAW 264.7 macrophages by modulating the activation of MAPK and NF-κB signaling pathways.</p>Fórmula:C14H8O5Cor e Forma:SolidPeso molecular:256.21OZO-H
CAS:OZO-H is a GST inhibitor and a potent anticancer derivative of OZO. It releases JNK1 from the GST-JNK1 complex, induces JNK1 phosphorylation, and activates c-Jun in cancer cells.Fórmula:C8H5NO2SCor e Forma:SolidPeso molecular:179.20PS-166276
CAS:<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Fórmula:C20H30N8OCor e Forma:SolidPeso molecular:398.51Luvometinib
CAS:<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Fórmula:C26H22F2IN5O4SCor e Forma:SolidPeso molecular:665.45HPK1-IN-30
CAS:HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.Fórmula:C25H23FN6Cor e Forma:SolidPeso molecular:426.49BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Fórmula:C35H33F6N7O2SPureza:97.879%Cor e Forma:SolidPeso molecular:729.74Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Fórmula:C32H31ClF2N6O4Pureza:98.69%Cor e Forma:SolidPeso molecular:637.08RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Fórmula:C27H24F3N7O2Cor e Forma:SolidPeso molecular:535.52PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Fórmula:C45H68N4OCor e Forma:SolidPeso molecular:681.05KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Fórmula:C24H28F3N5Cor e Forma:SolidPeso molecular:443.51
